Advertisement

Topics

Latest Gastroenterology NewsRSS

22:48 EDT 21st October 2017 | BioPortfolio

Judge tosses $417 million award in Johnson & Johnson baby powder cancer case

A California judge on Oct. 20, 2017, threw out a court ruling that ordered Johnson & Johnson to pay a record $417 million to a woman who alleged the company's talcum powder caused her cancer. A California judge on Oct. 20, 2017, threw out a court ruling that ordered Johnson & Johnson to pay a record $417 million to a woman who alleged the company's talcum powder caused her cancer.

Beacon Biomedical Inc Medical Equipment Deals and Alliances Profile [Report Updated: 12102017] Prices from USD $250

SummaryBeacon Biomedical Inc Beacon is a medical diagnostic device company that offers pointofcare blood test systems. The company offers its product portfolio in the therapeutic areas of breast cancer, colorectal cancer and lung cancer. It holds two patented technologies, signalling protein and pointofcare devices to develop and commercialize its pointofcare cancer screening and detection tests. ...

Helsinn Healthcare SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102017] Prices from USD $250

SummaryHelsinn Healthcare SA Helsinn Healthcare, a subsidiary of Helsinn Holding SA is a cancer care company that offers oncology products and therapies. The company offers products in therapeutic areas of pain and inflammation, cancer care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, KleanPrep and laxaclear. The company offers research and development programs...

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business. ...

Cancer Immunotherapy? There’s a Synthetic Gene Circuit for That

Approaching the immune system as though it were a work of engineering in need of improved cancer-fighting programming, MIT scientists have developed gene circuits that alter gene expression in cancer cells, causing the cancer cells to come to the notice of T cells, which respond by killing the cancer cells selectively, sparing healthy cells. The scientists say that their synthetic biology appr...

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better ... This awesome article Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene appeared first...

Breaking Bad: Cancer Cell Drug Addiction Solved

Cancer cells can become not only resistant but also addicted to the drugs that serve to kill them. A research team led by professor Daniel Peeper from the Netherlands Cancer Institute has now discovered the underlying mechanism, which may guide the development of more rational alternating therapies. They publish their findings in Nature on October 4th....

Global and Asia Budesonide Market Status and Future Forecast 20132023 [Report Updated: 06102017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Quest Diagnostics Acquires Cleveland HeartLab to Establish Cardiometabolic COE

Quest Diagnostics has signed a definitive agreement to acquire Cleveland HeartLab, a provider of innovative diagnostic services for managing cardiovascular disease. A spin-off of Cleveland Clinic, Cleveland HeartLab has created a specialized approach to identifying risk of heart disease, based in part on science published in more than 100 peer reviewed journals.  As part of ... Read More

Austrian Biotech Has Us Hooked with its Exciting Vaccine Technology

This week, we’ve headed to Vienna to take in some art, music and a biotech with one of the funkiest names in the industry – Hookipa.  Mission: Hookipa Biotech develops vaccines for infectious diseases and cancer. One of its platforms, TheraT fights cancer ... This awesome article Austrian Biotech Has Us Hooked with its Exciting Vaccine Technology appeared first on Labiotech.eu. Be ...

No Association Between Early Antibiotic Use and Risk for Diabetes or Celiac Disease

Use of ß-lactam or macrolide antibiotics early in life was not associated with risk for islet or celiac disease autoimmunity.

Global Oxaliplatin Market Analysis 20112017 and Forecast 20182023 [Report Updated: 22042017] Prices from USD $2980

SnapshotOxaliplatin is a platinumbased anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.The global Oxaliplatin market will reach xxx Million USD in 2017 and CAGR xx% 20112017. The report begins from overview of Industry Chain st...

STAT Plus: Cancer drug prices have been rising much, much faster than inflation

The mean price increase for 24 branded cancer medicines that were approved in the U.S. between 1996 and 2012 was a whopping 25 percent.

Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting

    Lund, October 19, 2017 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present new data on laquinimod, an investigational MS therapy in three presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and...

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that ... This awesome article Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech appeared first on Labio...

Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia

Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced the first patient has been dosed in an open-label study of SNX-5422 added to ibrutinib in chronic lymphocytic leukemia (CLL) subjects with residual disease (clinicaltrials.gov ID#

New Breast Cancer Combination from Norway Enters Phase II

BerGenBio will test its lead candidate, BGB324, in combination with Keytruda to stop advanced breast cancer in its tracks. BerGenBio develops AXL kinase inhibitors for multiple cancer indications. The company dosed its first patient in a Phase II trial to test ... This awesome article New Breast Cancer Combination from Norway Enters Phase II appeared first on Labiotech.eu. Be kind and don't copy ...

It's Breast Cancer Awareness Month: Healthy Lifestyle Choices to Ensure a Lifetime of Breast Health

In this article Dr. Shazah Khawaja MD of the Women’s OB/GYN Medical Group focuses on empowering women for Breast Cancer Awareness month by highlighting breast cancer prevention strategies. SANTA ROSA, Calif. (PRWEB) October 19, 2017 During October’s National Breast Cancer Awareness Campaign, The Women’s OB/GYN Medical Group is focusing on empowerment through knowledge leading to healthy cho...

Breast Cancer Recycles Toxic Waste to Restock Nitrogen for Growth

Scientists may have hit upon a new therapeutic strategy against breast cancer with the finding that breast tumor cells recycle the ammonia that is generated as a byproduct of normal cell metabolism  and use the toxic waste as a source of nitrogen to fuel their growth. The studies, by researchers at Harvard Medical School (HMS) and the Broad Institute of MIT and Harvard, showed that while cult...

Global Prostate Cancer Diagnostics Market Data Survey Report 2025 [Report Updated: 13102017] Prices from USD $1500

SummaryThe prostate is a walnutsized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but...

Vanderbilt Researchers Find Novel Mechanism Of Resistance To Anti-Cancer Drugs

NewsSome targeted anti-cancer therapies are mainstays of treatment for advanced colorectal cancer. However, many patients have tumors with genetic mutations that make them resistant to these antibodies, or the cancers develop resistance during treatment.

Novel Parkinson’s Therapy Suggested by New Research Findings

An international scientific team reports that they have shed light on the molecular mechanism underlying Parkinson's protein LRRK2. The group, which found a direct link between the protein's dimerization and mutations that lead to Parkinson's disease, believes their work could eventually lead to new therapies for this devastating disease. They report the results of their research (“A...

STAT Plus: Behold the power of magical thinking: How a tiny lung cancer study sent Spectrum’s stock soaring

Preliminary data on Spectrum's experimental lung cancer drug sent its share price soaring. Here's why investors should be more cautious.

Global Capecitabine Market Analysis 20112017 and Forecast 20182023 [Report Updated: 11102017] Prices from USD $2980

SnapshotCapecitabine is an orallyadministered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil antimetabolite in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.The global Capecitabine market will reach xxx Million USD in 2017 and CAGR xx% 20112017. The ...

20s Proteasome Pipeline Review, H2 2017 [Report Updated: 17102017] Prices from USD $3500

20s Proteasome Pipeline Review, H2 2017SummaryAccording to the recently published report '20s Proteasome Pipeline Review, H2 2017'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. 20s Proteasome 20S proteasome is the catalytic core of the 26S proteasome, the central p...

Quick Search
Advertisement
 

review and buy Gastroenterology market research data and corporate reports here